Xinyi Wang

Xinyi Wang

Auto-generated profile, based on publicly available information

Xinyi Wang

Wicking Dementia Research and Education Centre University of Tasmania Hobart Tasmania Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Human-Centric Intelligent Systems
Verified
Journal Article
Open access
PDF file
WYWenli Yang
Wenli Yang
YWYuchen Wei
Yuchen Wei
HWHanyu Wei
Hanyu Wei
YCYanyu Chen
Yanyu Chen
GHGuan Huang
Guan Huang
BKByeong Ho Kang
Byeong Ho Kang
In recent years, artificial intelligence (AI) technology has been used in most if not all domains and has greatly benefited our lives. While AI can accurately extract critical features and valuable information from large amounts of data to help people complete tasks faster, there are growing concerns about the non-transparency of AI in the decision-making process. The emergence of explainable AI (XAI) has allowed humans to better understand and control AI systems, which is motivated to provide transparent explanations for the decisions made by AI. This article aims to present a comprehensive overview of recent research on XAI approaches from three well-defined taxonomies. We offer an in-depth analysis and summary of the status and prospects of XAI applications in several key areas where reliable explanations are urgently needed to avoid mistakes in decision-making. We conclude by discussing XAI’s limitations and future research directions.

17 February 2022 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
RLRenjie Li
Renjie Li
XWXinyi Wang
Xinyi Wang
KLKatherine Lawler
Katherine Lawler
Saurabh GargSaurabh Garg
Saurabh Garg
Quan BaiQuan Bai
Quan Bai
Jane E. AltyJane E. Alty
Jane E. Alty

12 July 2021 in Health Information Science and Systems
Verified
Journal Article
Closed access
PDF file
XWXinyi Wang
Xinyi Wang
Saurabh GargSaurabh Garg
Saurabh Garg
STSon N. Tran
Son N. Tran
Quan BaiQuan Bai
Quan Bai
Jane E. AltyJane E. Alty
Jane E. Alty

21 June 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
RLRenjie Li
Renjie Li
RGRebecca J. St George
Rebecca J. St George
XWXinyi Wang
Xinyi Wang
KLKatherine Lawler
Katherine Lawler
EHEdward Hill
Edward Hill
Jane E. AltyJane E. Alty
Jane E. Alty

18 July 2022 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Jane E. AltyJane E. Alty
Jane E. Alty
Quan BaiQuan Bai
Quan Bai
RLRenjie Li
Renjie Li
KLKatherine Lawler
Katherine Lawler
RGRebecca J. St George
Rebecca J. St George
JVJames C. Vickers
James C. Vickers
Background: The worldwide prevalence of dementia is rapidly rising. Alzheimer’s disease (AD), accounts for 70% of cases and has a 10–20-year preclinical period, when brain pathology covertly progresses before cognitive symptoms appear. The 2020 Lancet Commission estimates that 40% of dementia cases could be prevented by modifying lifestyle/medical risk factors. To optimise dementia prevention effectiveness, there is urgent need to identify individuals with preclinical AD for targeted risk reduction. Current preclinical AD tests are too invasive, specialist or costly for population-level assessments. We have developed a new online test, TAS Test, that assesses a range of motor-cognitive functions and has capacity to be delivered at significant scale. TAS Test combines two innovations: using hand movement analysis to detect preclinical AD, and computer-human interface technologies to enable robust ‘self-testing’ data collection. The aims are to validate TAS Test to [1] identify preclinical AD, and [2] predict risk of cognitive decline and AD dementia.Methods: Aim 1 will be addressed through a cross-sectional study of 500 cognitively healthy older adults, who will complete TAS Test items comprising measures of motor control, processing speed, attention, visuospatial ability, memory and language. TAS Test measures will be compared to a blood-based AD biomarker, phosphorylated tau 181 (p-tau181). Aim 2 will be addressed through a 5-year prospective cohort study of 10,000 older adults. Participants will complete TAS Test annually and subtests of the Cambridge Neuropsychological Test Battery (CANTAB) biennially. 300 participants will undergo in-person clinical assessments. We will use machine learning of motor-cognitive performance on TAS Test to develop an algorithm that classifies preclinical AD risk (p-tau181-defined) and determine the precision to prospectively estimate 5-year risks of cognitive decline and AD.Discussion: This study will establish the precision of TAS Test to identify preclinical AD and estimate risk of cognitive decline and AD. If accurate, TAS Test will provide a low-cost, accessible enrichment strategy to pre-screen individuals for their likelihood of AD pathology prior to more expensive tests such as blood or imaging biomarkers. This would have wide applications in public health initiatives and clinical trials.Trial registration: ClinicalTrials.gov Identifier:NCT05194787, 18 January 2022. Retrospectively registered.

17 August 2023 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Open access
Jane E. AltyJane E. Alty
Jane E. Alty
KLKatherine Lawler
Katherine Lawler
KSKatharine Salmon
Katharine Salmon
SMScott McDonald
Scott McDonald
KSKimberley Stuart
Kimberley Stuart
JVJames C. Vickers
James C. Vickers
Objectives: Unequal access to cognitive assessments is a major barrier to timely diagnosis, especially for those living in rural or remote areas. ‘One‐stop’ cognitive clinic models are a proposed solution, but few such clinics exist. We evaluate the implementation of a new one‐stop State‐wide clinic model in Tasmania, Australia, where 27% of people live in rural/remote areas.Methods: A novel single‐visit protocol has been developed, comprising interdisciplinary medical and cognitive assessments, research participation, consensus diagnosis and management plan. A cross‐sectional evaluation was undertaken using the RE‐AIM (reach, effectiveness, adoption, implementation, maintenance) framework and results benchmarked against the national Australian Dementia Network Registry.Results: Over the first 52 consecutive weekly clinics: Reach: 130 adults were assessed (mean age [SD] 70.12 years [10.31]; 59.2% female) with 40 (36.8%) from rural/remote areas. Effectiveness: 98.5% (128/130) received a same‐day diagnosis: 30.1% (n = 40) Subjective Cognitive Decline, 35.4% (46) Mild Cognitive Impairment, 33.1% (43) dementia and one case inconclusive. Adoption: 22.9% (156) of General Practitioners referred patients. Implementation: Nearly all ‘ideal’ diagnostic clinical practices were met and >90% of surveyed patients reported ‘good/very good’ clinic experience. The wait from referral to diagnosis was 2 months shorter than other national Registry clinics (78 vs. 133 days).Conclusions: This ‘one‐stop’ model provides an interdisciplinary consensus cognitive diagnosis quickly and is well accepted; this may reduce health inequities especially for people living in rural/remote areas. This cognitive clinic model may be of relevance to other centres worldwide and also provides a rich data source for research studies.